Department of Hematology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan.
Department of Hematology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Cancer Sci. 2019 Jan;110(1):401-407. doi: 10.1111/cas.13848. Epub 2018 Nov 18.
Primary central nervous system lymphoma (PCNSL) is a rare subtype of lymphoma that arises within the brain or the eyes. PCNSL recurs within the central nervous system (CNS) in most relapsed cases, whereas extra-CNS relapse is experienced in rare cases. The present study aimed at identifying the presence of common precursor cells (CPC) for primary intra- and relapsed extra-CNS tumors, and further assessing the initiating events in bone marrow (BM). Targeted deep sequencing was carried out for five paired primary intra- and relapsed extra-CNS tumors of PCNSL. Two to five mutations were shared by each pair of intra- and extra-CNS tumors. In particular, MYD88 mutations, L265P in three and P258L in one, were shared by four pairs. Unique somatic mutations were observed in all five intra-CNS tumors and in four out of five extra-CNS tumors. Remarkably, IgH clones in the intra- and the extra-CNS tumors in two pairs were distinct from each other, whereas one pair of tumors shared identical monoclonal IgH rearrangement. In a cohort of 23 PCNSL patients, L265P MYD88 mutations were examined in tumor-free BM mononuclear cells (MNC) in which the PCNSL tumors had L265P MYD88 mutations. L265P MYD88 mutations were detected by a droplet digital PCR method in nine out of 23 bone marrow mononuclear cells. These results suggest that intra- and extra-tumors are derived from CPC with MYD88 mutations in most PCNSL, arising either before or after IgH rearrangement. The initiating MYD88 mutations may occur during B-cell differentiation in BM.
原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的淋巴瘤亚型,发生于脑或眼内。在大多数复发性病例中,PCNSL 会在中枢神经系统(CNS)内复发,而在极少数情况下会出现 CNS 外复发。本研究旨在鉴定原发性颅内和复发的 CNS 外肿瘤的常见前体细胞(CPC),并进一步评估骨髓(BM)中的起始事件。对 5 对原发性颅内和复发的 CNS 外 PCNSL 肿瘤进行了靶向深度测序。每对内、外 CNS 肿瘤之间存在 2-5 个共享突变。特别是,MYD88 突变,三个存在 L265P,一个存在 P258L,在四个配对中共享。在所有 5 个颅内肿瘤和 5 个 CNS 外肿瘤中的 4 个中观察到独特的体细胞突变。值得注意的是,在两对肿瘤中,颅内和 CNS 外肿瘤中的 IgH 克隆彼此不同,而一对肿瘤则共享相同的单克隆 IgH 重排。在 23 例 PCNSL 患者队列中,在肿瘤无负荷 BM 单核细胞(MNC)中检查了无 L265P MYD88 突变的 PCNSL 肿瘤中的 L265P MYD88 突变。通过液滴数字 PCR 方法在 23 个骨髓单核细胞中的 9 个中检测到 L265P MYD88 突变。这些结果表明,在大多数 PCNSL 中,L265P MYD88 突变的 CPC 是颅内和 CNS 外肿瘤的来源,这些突变发生在 IgH 重排之前或之后。起始的 MYD88 突变可能发生在 BM 中的 B 细胞分化过程中。